Explore how recent advancements in cancer care impact the insurance industry, focusing on CAR T-cell therapy and regulatory compliance.

Explore the complexities of prior authorizations in health insurance, emphasizing coordination among providers and the need for timely updates in medical guidelines.

Explore the challenges of patient enrollment in cancer clinical trials and how insurance reforms can improve accessibility for those in need.

CMS announces a 9.7% increase in Medicare Part B premiums for 2026, affecting individuals earning $109,000 or less. Updates on oncology drug reimbursement and legal challenges to the CMS 340B drug rebate pilot program highlight shifting dynamics in Medicare regulation and healthcare compliance.

In 2025, Medicare Part D caps oral cancer drug out-of-pocket costs at $2,000, introducing a monthly payment plan to aid affordability and adherence for beneficiaries.

The 2024 cancer report highlights declines in US cancer mortality through 2022, with 2020 pandemic-related diagnosis drops not persisting into 2021. Key insights for oncology insurers and providers.